최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기환경독성학회지 = Journal of environmental toxicology, v.24 no.1, 2009년, pp.71 - 77
Adenoviral vector(AdV) has been the most widely used viral vector for delivering an exogenous therapeutic gene to human. As of this date, more clinical trials utilize recombinant AdV to treat cancer and monogenic inherited disease as well as vaccine applications. However, the number of clinical tria...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
AdV-p53은 무엇인가? | , 2004)이다. AdV-p53는 종양억제유전자인 p53을 AdV에 재조합한 것이다. P53 단백질의 발견에서부터 유전자치료제로의 개발, 임상실험 등은 미국에서 주도하였고 엄청난 개발 비용을 들였지만 시장 판매 허가의 주관심이 암환자의 생존율이었던 미국에서는 허가가 나오지 않았다. | |
아데노바이러스 벡터를 매개한 유전자치료의 적용 대상 범위는 어떠한가? | 바이러스 벡터 중 아데노바이러스 벡터(adenoviral vector, AdV)는 유전자치료 (gene therapy)에서 외래성 치료 유전자(therapeutic gene)를 인체에 전달하는 데 가장 많이 사용되고 있는 전달도구이다. AdV를 매개한 유전자치료의 적용 대상 범위도 암뿐만이 아니라 단일유전성 유전질환, 최근에는 백신으로 까지 확대되고 있다. | |
아데노바이러스 벡터는 무엇에 사용되는 전달도구인가? | 즉, 기대하는 치료 효과를 얻기 위해 전이하고자 하는 유전자를 바이러스 게놈에 삽입을 한 후, 본래 바이러스가 지니고 있는 세포 변환 능력을 활용하는 것이다. 바이러스 벡터 중 아데노바이러스 벡터(adenoviral vector, AdV)는 유전자치료 (gene therapy)에서 외래성 치료 유전자(therapeutic gene)를 인체에 전달하는 데 가장 많이 사용되고 있는 전달도구이다. AdV를 매개한 유전자치료의 적용 대상 범위도 암뿐만이 아니라 단일유전성 유전질환, 최근에는 백신으로 까지 확대되고 있다. |
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL and Finberg RW. Isolation of a common receptor for cosackie B viruses and adenoviruses 2 and 5, Science 1997; 275 (5304): 1320-1323
Boquet MP, Wonganan P, Dekker JD, Croyle MA. Influence of method of systemic administration of adenovirus on virusmediated toxicity: focus on mortality, virus distribution, and drug metabolism, J Pharmacol Toxicol Methods 2008; 58(3): 222-232
Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG and Lowenstein PR. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials, Nat Med 1999; 5: 1256-1263
Dormond E, Perrier M and Kamen A. From the first to the third generation adenoviral vector: What parameters are governing the production yield? Biotechnol Advances 2009; 27(2): 133-144
Driesse MJ, Vincent AJ, Sillevis Smitt PA, Kros JM, Hoogerbrugge PM, Avezaat CJ, Valerio D and Bout A. Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates, Gene Ther 1998; 5: 1122-1129
Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J and Poller W. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers, Gene Ther 1999; 6: 1520-1535
Garcia-Banuelos J, Siller-Lopez F, Miranda A, Aguilar LK, Aguilar-Cordova E and Armendariz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion, Gene Ther 2002; 9: 127-134
Gomez-Manzano C, Yung WK, Alemany R and Fueyo J. Genetically modified adenoviruses against gliomas: from bench to bedside, Neurol 2004; 63: 418-426
Krebs P, Scandella E, Odermatt B and Ludewig B. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus, J Immunol 2005; 174: 4559-4566
Manickan E, Smith JS, Tian Jie, Eggerman TL, Lozier JN, Muller J and Byrnes AP. Rapid Kupffer cell death after intravenous injection of adenovirus vectors, Mol Ther 2006; 13(1): 108-117
Markus JV, Vaha-Koskela B, Heikkila JE and Hinkkanen AE. Oncolytic viruses in cancer therapy, Cancer Letters 2007; 254(2): 178-216
Massari I, Donnini A, Argentati K, Straino S, Mangoni A, Gaetano C, Viticchi C, Capogrossi M and Provinciali M. Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats, Exp Gerontol 2002; 37: 823-831
McConnell MJ and Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy, Human Gene Ther 2004; 15(11): 1022-1033
Morrissey RE, Horvath C, Snyder EA, Patrick J, Collins N, Evans E and MacDonald JS. Porcine toxicology studies of SCH 58500, an adenoviral vector for the p53 gene, Toxicol Sciences 2002a; 65(2): 256-265
Morrissey RE, Horvath C, Snyder EA, Patrick J and Mac- Donald JS. Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene, Toxicol Sciences 2002b; 65(2): 266-275
Pearson S, Jia H and Kandachi K. China approves first gene therapy. Nat Biotechnol 2004; 22(1): 3-4
Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen TD, Ranki T, Sarkioja M, Kangasniemi L and Hemminki A. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer, Gene Ther 2005; 12: 1198-1205
Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, Wilson JM and Batshaw ML. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Human Gene Ther 2002; 13(1): 163-175
Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao G, Wilson JM and Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol Genet Met 2003; 80(1-2): 148-158
Raper SE. Gene therapy: The good, the bad, and the ugly, Surgery 2005; 137(5): 487-492
Su C, Cao H, Tan S, Huang Y, Jia X JL, Wang K, Chen Y, Long J, Liu X, Wu M, Wu X and Qian Q. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates, Toxicol Sciences 2008; 106(1): 242-250
Thomas CE, Birkett D, Anozie I, Castro MG and Lowenstein PR. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain, Mol Ther 2001; 3(1): 36-46
Tripathy SK, Goldwasser MM, Lu EB and Leiden JM. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus, Proc Natl Acad Sci USA 1994; 91: 11557-11561
Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu X, The BS, Butler EB, Woo S, Thompson TC, Barrera-Saldana H and guilar-Cordova E. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model, Mol Ther 2002; 6: 342-348
Wickham TJ, Mathias P, Cheresh DA and Nemerow G. Integrins ${\alpha}v{\beta}3$ and ${\alpha}v{\beta}5$ promote adenovirus internalization but not virus attachment, Cell 1993; 73: 309-319
Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, Tazelaar J and Wilson JM. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages, Mol Ther 2001; 3(51): 697-707
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.